iTeos Therapeutics to Participate in Upcoming Conferences in November
Gosselies, Belgium – November 7, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that management will participate in two upcoming conferences in November.
- Management will be available for one-on-one meetings at the Jefferies 2018 London Healthcare Conference from November 14-15, 2018 in London, UK.
- Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 9:30 a.m. ET in New York, NY.
About iTeos Therapeutics
iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.
For further information, please contact:
Michel Detheux, CEO
iTeos Therapeutics
info@iteostherapeutics.com
Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com
Sarah McCabe and Carl Mauch
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos@sternir.com